Pregnancy and Delivery Under Bromocriptine Therapy

Espersen, T; Ditzel, Jørn

doi:10.1016/s0140-6736(77)90937-0

Cited by 26 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…growth retardation;= caesarean sections, after Weeks 36 and 37, in the same patient, the first time because of intra-uterine growth retardation, no explanation being given for the second time.= There was 1 spontaneous abortion,156 1 premature spontaneous delivery after 31 weeks,152 and 1 premature spontaneous delivery during Week 33. 57 Birth weights below 2500 g were seen in 6 infants: 1515 g,152 1550 g,87 1580 g,57 2190 g,88 2350 g145 and 2470 g.49 All but 2 children were healthy. One child had a balanced translocation involving chromosomes 8 and 12, which was not clinically evident; the abnormality was present in neither parent.72(Schellekens et al investigated the chromosome patterns of 19 children born to mothers treated with bromocriptine before conception and in early pregnancy, and the only abnormality they found was one of chromosome 6 in 1 child, a feature also present in the mother.)…”

Section: Various Conditionsmentioning

confidence: 97%

The safety of bromocriptine in long-term use: a review of the literature

Weil

1986

Current Medical Research and Opinion

View full text Add to dashboard Cite

This paper reviews the safety data on bromocriptine administration for 1 to 10 years at daily doses of 1.25 to 80 mg in over 1100 patients with pituitary hormone overproduction (mainly from prolactinomas and growth-hormone producing adenomas), at daily doses of 3.75 to 170 mg in over 700 patients with Parkinson's disease, and at daily doses of 2.5 to 20 mg in 28 patients with various other conditions. In addition, information is provided on the safety for mother and child of bromocriptine administered at daily doses of 2.5 to 35 mg throughout gestation (54 pregnancies) or during its later stages (39 pregnancies). The side-effects of long-term bromocriptine treatment are usually no different from those seen during short-term treatment; most of them are relatively benign, and they have been shown in virtually all patients to be reversible. Bromocriptine appears to have no harmful effect on hepatic, renal, haematologic, or cardiac functions. It is considered that a hitherto unknown, severe though rare side-effect of bromocriptine is unlikely to be reported after such long experience.

show abstract

Section: Various Conditionsmentioning

confidence: 97%

The safety of bromocriptine in long-term use: a review of the literature

Weil

1986

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

“…The majority of reported cases were treated with bromocriptine only (14 -16) or in conjunction with radiation (22,23) or surgery (24). Bromocriptine was not associated with teratogenicity or fetoplacental insufficiency in three cases (14 -16); however, prematurity was reported in one patient (16), and intrauterine growth delay (13,23) has been reported in two cases. There are four cases (including our two cases) of pregnancy ensuing after successful treatment of acromegaly with octreotide (17,18).…”

Section: Acromegaly and Fertilitymentioning

confidence: 99%

Pregnancy in Acromegaly: Successful Therapeutic Outcome¹

Herman-Bonert

Seliverstov

Melmed

1998

The Journal of Clinical Endocrinology & Metabolism

View full text Add to dashboard Cite

“…In addition, a long term follow up study by Raymond et al 25 of 64 infants and children (six months to nine years) whose mothers took bromocriptine for the first four weeks of gestation have shown no increase in abnormalities. Furthermore, in the event of tumour expansion in pregnancy, bromocriptine has been used successfully, with no ill effects on the infant 23,26 . The information on safety in pregnancy for other dopamine agonists, such as cabergoline and quinagolide, is limited at present.…”

Section: Pregnancy In Women With Prolactinomasmentioning

confidence: 99%